[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554219":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":22,"id":49,"slug":22,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":22,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":22,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"NewAmsterdam Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"obicetrapib\u002Fevolocumab combination","EXPERIMENTAL","obicetrapib 10 mg\u002FdL daily for 8 weeks followed by obicetrapib 10 mg\u002FdL daily + evolocumab 140 mg\u002FdL every other week for 8 weeks",[13],"Drug: obicetrapib 10 mg + obicetrapib\u002Fevolocumab 140 mg Q 2 weeks",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","obicetrapib 10 mg + obicetrapib\u002Fevolocumab 140 mg Q 2 weeks","10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib\u002F 140 mg evolocumab (every 2 weeks) combination for 8 weeks",[9],[21],"Repatha",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Ashley Walker","CONTACT","919 641 5724","ashley.walker@newamsterdampharma.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"UPenn","RECRUITING","Philadelphia","Pennsylvania","19104","United States",{"type":38,"coordinates":39},"Point",[40,41],-75.16362,39.95238,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":22,"phoneExt":22,"email":22},"Archna Bajaj","PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100554219",false,"NCT06496243","Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels","A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study","VINCENT","Inclusion Criteria:\n\n* Lp(a): \\>=50 mg\u002FdL (\\>=125 nmol\u002FL) for cohort 1 (FILLED) and Lp(a) \\>= 20 mg\u002FdL (\\>= 50 nmol\u002FL) to \\\u003C50 mg\u002FdL (\\\u003C 125 nmol\u002FL) for cohort 2\n* LDL-C \\>70 mg\u002FdL\n* TG \\\u003C 400mg\u002FdL (\\\u003C4.52 mmol\u002FL)\n\nExclusion Criteria:\n\n* HbA1c\\>=10 or FPG \\>=270 mg\u002FdL\n* CV events within 3 months of screen","ALL","18 Years","75 Years",{"count":60,"type":61},69,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib\u002Fevolocumab\n\nPatients will:\n\nHave baseline Lp(a) tested at randomization Take 10mg\u002FdL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg\u002FdL obicetrapib daily\u002Fevolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16",[67],"Dyslipidemias","2026-04-06",{"date":70,"type":71},"2026-04-09","ACTUAL",{"date":73,"type":71},"2024-12-02",{"date":75,"type":61},"2027-02",{"name":5,"class":6},1]